Compare · ITGR vs NXL
ITGR vs NXL
Side-by-side comparison of Integer Holdings Corporation (ITGR) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITGR and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $3.12B, about 289.8x NXL ($10.8M).
- Over the past year, ITGR is down 24.6% and NXL is down 59.6% - ITGR leads by 35.0 points.
- ITGR has been more active in the news (16 items in the past 4 weeks vs 4 for NXL).
- ITGR has more recent analyst coverage (23 ratings vs 0 for NXL).
- Company
- Integer Holdings Corporation
- Nexalin Technology Inc.
- Price
- $92.11-0.63%
- $0.51+0.51%
- Market cap
- $3.12B
- $10.8M
- 1M return
- +6.59%
- +45.49%
- 1Y return
- -24.58%
- -59.55%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 16
- 4
- Recent ratings
- 23
- 0
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Latest ITGR
- Integer to Participate in Truist Securities 2026 MedTech Conference on June 16
- Director Maxwell Martin C was granted 1,967 shares, increasing direct ownership by 9% to 25,106 units (SEC Form 4)
- SEC Form 4 filed by Director Hinrichs James F.
- Director Coyle Michael J was granted 1,967 shares, increasing direct ownership by 145% to 3,322 units (SEC Form 4)
- Director Kapito Aaron was granted 1,967 shares, increasing direct ownership by 144% to 3,338 units (SEC Form 4)
- Director Capps Cheryl C was granted 1,967 shares, increasing direct ownership by 17% to 13,669 units (SEC Form 4)
- Director Jeffers Alvin Tyrone was granted 1,967 shares, increasing direct ownership by 76% to 4,552 units (SEC Form 4)
- Director Antrum Sheila was granted 1,967 shares, increasing direct ownership by 19% to 12,069 units (SEC Form 4)
- Director Passerini Filippo was granted 1,967 shares, increasing direct ownership by 7% to 31,114 units (SEC Form 4)
- Director Flanagan James Francis was granted 1,967 shares, increasing direct ownership by 480% to 2,377 units (SEC Form 4)
Latest NXL
- Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
- Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
- SEC Form 10-Q filed by Nexalin Technology Inc.
- Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
- Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
- Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents